{"id":"comparator-amlodipine-besylate","safety":{"commonSideEffects":[{"rate":"8-10","effect":"Peripheral edema"},{"rate":"7-8","effect":"Headache"},{"rate":"4-6","effect":"Flushing"},{"rate":"4-5","effect":"Fatigue"},{"rate":"3-4","effect":"Dizziness"},{"rate":"2-3","effect":"Palpitations"}]},"_chembl":{"chemblId":"CHEMBL1200402","moleculeType":"Small molecule","molecularWeight":"567.06"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Amlodipine selectively blocks L-type calcium channels in the membranes of vascular smooth muscle and cardiac muscle cells. By preventing calcium entry, it reduces intracellular calcium concentration, leading to vasodilation and decreased peripheral vascular resistance. This results in reduced blood pressure and improved coronary blood flow, making it effective for both hypertension and angina.","oneSentence":"Amlodipine besylate is a calcium channel blocker that relaxes blood vessels and reduces blood pressure by inhibiting calcium influx into vascular smooth muscle cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:06:49.465Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension"},{"name":"Angina pectoris (chronic stable angina and vasospastic angina)"}]},"trialDetails":[{"nctId":"NCT05780710","phase":"NA","title":"OBPM_Meds2023: Multicentric Prospective Clinical Study to Evaluate the Aktiia Optical Blood Pressure Monitoring (OBPM) Device Compared to Standard Home Blood Pressure Monitoring (HBPM) in Hypertensive Patients When Blood Pressure Lowering Medications Intake","status":"RECRUITING","sponsor":"Aktiia SA","startDate":"2023-06-29","conditions":"Hypertension","enrollment":35},{"nctId":"NCT07262710","phase":"","title":"Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With Post-Stroke Pneumonia: A Real-World Retrospective Cohort Study","status":"NOT_YET_RECRUITING","sponsor":"First Teaching Hospital of Tianjin University of Traditional Chinese Medicine","startDate":"2025-12-01","conditions":"Post-stroke Pneumonia","enrollment":13656},{"nctId":"NCT02373163","phase":"PHASE4","title":"INTERVENCION Trial","status":"COMPLETED","sponsor":"Prevencion","startDate":"2014-09-01","conditions":"Blood Pressure, High","enrollment":166},{"nctId":"NCT05920005","phase":"PHASE3","title":"Candesartan Cilexetil + Chlorthalidone + Amlodipine Versus Exforge HCT®️ for Systemic Arterial Hypertension","status":"COMPLETED","sponsor":"Hospital Israelita Albert Einstein","startDate":"2023-08-22","conditions":"Hypertension","enrollment":702},{"nctId":"NCT06293261","phase":"","title":"Multicenter, Prospective, Non-interventional, Observational Study to Confirm the Long-term Efficacy and Safety of Rosuampin Tab. in Patients With Hypertension and Hypercholesterolemia","status":"COMPLETED","sponsor":"Yuhan Corporation","startDate":"2020-06-27","conditions":"Hypertension, Hypercholesterolemia","enrollment":5047},{"nctId":"NCT03662620","phase":"PHASE1","title":"Clinical Trial to Compare the Safety and Pharmacokinetics of YH22162 in Healthy Volunteers","status":"COMPLETED","sponsor":"Yuhan Corporation","startDate":"2018-10-05","conditions":"Hypertension","enrollment":67},{"nctId":"NCT00140959","phase":"PHASE4","title":"Losartan and HCTZ and Amlodipine vs Atenolol and Amlodipine (0954A-309)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2003-02-01","conditions":"Hypertension","enrollment":120},{"nctId":"NCT00568178","phase":"PHASE3","title":"An Extension Study Designed to Assess Effects of Losartan on Proteinuria in Pediatric Populations (MK-0954-326 AM1,EXT1(AM2))","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2007-06-01","conditions":"Proteinuria","enrollment":306},{"nctId":"NCT05189015","phase":"PHASE4","title":"Effect of Olmesartan on Angiotensin(1-7) Levels and Vascular Functions in Diabetes and Hypertension","status":"COMPLETED","sponsor":"Seoul National University Bundang Hospital","startDate":"2021-01-01","conditions":"Angiotensin/Renin/Aldosterone Hypertension, Hypertension, Diabetes Mellitus, Type 2","enrollment":80},{"nctId":"NCT05173025","phase":"PHASE4","title":"Effect of Fimasartan on Extended RAS and Vascular Functions in Patients With Type 2 Diabetes and Hypertension","status":"UNKNOWN","sponsor":"Seoul National University Bundang Hospital","startDate":"2018-01-01","conditions":"Hypertension, Atherosclerosis, Diabetes Mellitus, Type 2","enrollment":42},{"nctId":"NCT05843162","phase":"PHASE4","title":"A Clinical Trial to Evaluate the Blood Pressure Control of Telmisartan or Losartan in Essential Hypertensive Patients With Metabolic Syndrome","status":"UNKNOWN","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2023-06-01","conditions":"Essential Hypertension, Metabolic Syndrome","enrollment":116},{"nctId":"NCT04929600","phase":"PHASE4","title":"Sacubitril/Valsartan Versus Amlodipine in Hypertension and Left Ventricular Hypertrophy.","status":"UNKNOWN","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2021-11-28","conditions":"Hypertension, Left Ventricular Hypertrophy","enrollment":120},{"nctId":"NCT03897868","phase":"PHASE2","title":"A Phase 2 Study to Assess Dose-response Relationship of HCP1803 in Patients With Essential Hypertension","status":"COMPLETED","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2019-03-21","conditions":"Hypertension","enrollment":248},{"nctId":"NCT00140985","phase":"PHASE4","title":"Antiproteinuric Efficacy of Losartan Potassium in Patients With Non-Diabetic Proteinuric Renal Diseases (0954-213)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2000-02","conditions":"Renal Disorder","enrollment":97},{"nctId":"NCT03991442","phase":"PHASE3","title":"BR1010 in Patients With Essential Hypertension Patients Who do Not Adequately Respond to Fimasartan/Amlodipine Combination","status":"COMPLETED","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2019-06-17","conditions":"Essential Hypertension","enrollment":257},{"nctId":"NCT04218552","phase":"PHASE2","title":"Determining the Optimal Dose of AD-209 in Patients With Essential Hypertension","status":"COMPLETED","sponsor":"Addpharma Inc.","startDate":"2020-02-25","conditions":"Hypertension,Essential","enrollment":176},{"nctId":"NCT04074551","phase":"PHASE3","title":"A Phase 3 Study to Compare the Efficacy and Safety of Co-administered HGP0608, HGP0904 and HCP1306 Versus HCP1701 in Patients With Hypertension and Dyslipidemia","status":"COMPLETED","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2019-07-16","conditions":"Hypertension, Dyslipidemias","enrollment":145},{"nctId":"NCT01302691","phase":"PHASE3","title":"MK-0954E Study in Participants With Hypertension (MK-0954E-357)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-01-01","conditions":"Hypertension","enrollment":327},{"nctId":"NCT03635125","phase":"PHASE4","title":"Efficacy and Safety of Nebivolol Versus Metoprolol in Hypertensive Subject Taking Amlodipine","status":"COMPLETED","sponsor":"Trinity Hypertension & Metabolic Research Institute","startDate":"2010-08-30","conditions":"JNC 7 Stage 1 or 2 Hypertension","enrollment":40},{"nctId":"NCT02974439","phase":"PHASE1","title":"Bioequivalence Study of Amlodipine and Norvasc Under Fasting and FED Conditions in Chinese Healthy Volunteers","status":"COMPLETED","sponsor":"Shanghai Haini Pharmaceutical Co., Ltd.","startDate":"2016-12-23","conditions":"Bioequivalence","enrollment":60},{"nctId":"NCT02312375","phase":"NA","title":"Effects of Fimasartan on Insulin Secretion in Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2015-03","conditions":"Diabetes Mellitus, Hypertension","enrollment":46},{"nctId":"NCT02707913","phase":"PHASE1","title":"Clinical Bioequivalence Study on Two Amlodipine Tablet 10mg Formulations","status":"COMPLETED","sponsor":"Bright Future Pharmaceuticals Factory O/B Bright Future Pharmaceutical Laboratories Limited","startDate":"2016-03","conditions":"Healthy","enrollment":17},{"nctId":"NCT01130168","phase":"PHASE1","title":"The Effects of Antihypertensive Agents on Central Blood Pressure in Healthy Participants and Participants With Hypertension (MK-0000-166) (COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-05","conditions":"Hypertension","enrollment":38},{"nctId":"NCT00789321","phase":"PHASE1","title":"A Study to Evaluate Methodologies for Measuring Swelling of the Leg and Ankle (MK-0000-106)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-07","conditions":"Hypertension","enrollment":47},{"nctId":"NCT01819220","phase":"PHASE4","title":"Randomized, Open Labeled Clinical Trial to Compare the Effectiveness of Amlodipine/Valsartan vs Hydrochlorothiazide/Telmisartan on Glucose Tolerance in Patients With Hypertension With Metabolic Syndrome","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2009-04","conditions":"Hypertension","enrollment":16},{"nctId":"NCT01865188","phase":"PHASE3","title":"Study of the Efficacy and Safety of LCZ696 Alone and in Combination With Amlodipine in Patients With Hypertension","status":"WITHDRAWN","sponsor":"Novartis Pharmaceuticals","startDate":"2014-04","conditions":"Hypertension","enrollment":""},{"nctId":"NCT01278797","phase":"PHASE1","title":"Telmisartan and Amlodipine Versus Monocomponent Tablets","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2011-01","conditions":"Hypertension","enrollment":28},{"nctId":"NCT01432106","phase":"PHASE1","title":"The Study of Novel Dual Renin Angiotensin Aldosterone System (RAAS) Blockade; Valsartan/Aliskiren in African American Patients With Hypertension and the Metabolic Syndrome","status":"WITHDRAWN","sponsor":"University of Michigan","startDate":"2011-02","conditions":"Hypertension, Metabolic Syndrome","enrollment":""},{"nctId":"NCT00834600","phase":"NA","title":"Renin Profiling in Selection of Initial Antihypertensive Drug","status":"COMPLETED","sponsor":"The Louis & Rachel Rudin Foundation","startDate":"2005-12","conditions":"Hypertension","enrollment":185},{"nctId":"NCT00950066","phase":"PHASE2","title":"Irbesartan and Amlodipine Combination in Controlling Blood Pressure","status":"COMPLETED","sponsor":"Sanofi","startDate":"2009-07","conditions":"Hypertension","enrollment":270},{"nctId":"NCT00870142","phase":"PHASE1","title":"A Relative Bioavailability Study of Amlodipine Besylate 10 mg Tablets Under Fasting Conditions","status":"COMPLETED","sponsor":"Actavis Inc.","startDate":"2005-04","conditions":"Healthy","enrollment":26},{"nctId":"NCT00870571","phase":"PHASE1","title":"A Relative Bioavailability Study of Amlodipine Besylate 10 mg Tablets Tablets Under Fed Conditions","status":"COMPLETED","sponsor":"Actavis Inc.","startDate":"2005-04","conditions":"Healthy","enrollment":26}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":187,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["NORVASC®"],"phase":"phase_3","status":"active","brandName":"Comparator: amlodipine besylate","genericName":"Comparator: amlodipine besylate","companyName":"Organon and Co","companyId":"organon-and-co","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Amlodipine besylate is a calcium channel blocker that relaxes blood vessels and reduces blood pressure by inhibiting calcium influx into vascular smooth muscle cells. Used for Hypertension, Angina pectoris (chronic stable angina and vasospastic angina).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}